「the first」の検索結果
23件：6～10件目を表示
-
製品開発方針 | 研究開発活動 | 千寿製薬株式会社
開発に挑戦し続けています。 #1:井上 佐智子, 川島 素子, 坪田 一男：ドライアイとは？原因から最新の治療まで、ファルマシア, 2014 50(3): 201-6 #2: Papas EB. The global prevalence of dry eye disease: A Bayesian view. Ophthalmic Physiol Opt. 2021;41(6):1254-6...
https://www.senju.co.jp/rd/policy/ -
产品开发方针 | 研究与开发 | 千寿制药株式会社
发，从而为患者带去希望。 #1: 井上 佐智子, 川岛 素子, 坪田 一男：什么是干眼症？从原因到最新的治疗，Farumashia，2014 50(3): 201-6 #2: Papas EB. The global prevalence of dry eye disease: A Bayesian view. Ophthalmic Physiol Opt. 2021;41(6):1254-6...
http://www.senju.co.jp/chinese/rd/policy/ -
Management Policy | About Senju | SENJU Pharmaceutical
valuable for society, we are committed to pursuing happiness for all people associated with Senju rather than just becoming a “big company” that pursues only greater growth and increased sales. Action...
http://www.senju.co.jp/english/about/philosophy.html -
ers: Osaka, Japan; President: Mr. Shuhei Yoshida) today announces that it has received approval for the marketing of “Mytear Lumify” (OTC drug requiring instruction by pharmacist, hereinafter this &qu...
https://www.senju.co.jp/system/files/content_news/2024-08/ENG_20240903.pdf -
ers: Osaka, Japan; President: Mr. Shuhei Yoshida) today announces that it has received approval for the marketing of “Mytear Lumify” (OTC drug requiring instruction by pharmacist, hereinafter this &qu...
https://www.senju.co.jp/system/files/content_news/2024-08/ENG_20240903_0.pdf